Article Versions Notes

Astolfi A, Milano F, Palazzotti D, Brea J, Pismataro MC, Morlando M, Tabarrini O, Loza MI, Massari S, Martelli MP, et al. From Serendipity to Rational Identification of the 5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one Core as a New Chemotype of AKT1 Inhibitors for Acute Myeloid Leukemia. Pharmaceutics. 2022; 14(11):2295. https://doi.org/10.3390/pharmaceutics14112295

Astolfi, Andrea, Francesca Milano, Deborah Palazzotti, Jose Brea, Maria Chiara Pismataro, Mariangela Morlando, Oriana Tabarrini, Maria Isabel Loza, Serena Massari, Maria Paola Martelli, and et al. 2022. "From Serendipity to Rational Identification of the 5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one Core as a New Chemotype of AKT1 Inhibitors for Acute Myeloid Leukemia" Pharmaceutics 14, no. 11: 2295. https://doi.org/10.3390/pharmaceutics14112295

Astolfi, A., Milano, F., Palazzotti, D., Brea, J., Pismataro, M. C., Morlando, M., Tabarrini, O., Loza, M. I., Massari, S., Martelli, M. P., & Barreca, M. L. (2022). From Serendipity to Rational Identification of the 5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one Core as a New Chemotype of AKT1 Inhibitors for Acute Myeloid Leukemia. Pharmaceutics, 14(11), 2295. https://doi.org/10.3390/pharmaceutics14112295